DeVita

ModernFi Raises $18.7M Series A to Power Deposit Growth at Community and Regional Banks

Retrieved on: 
Tuesday, January 23, 2024
Professional Services, Technology, Finance, Software, Fintech, Banking, Entrepreneurship, Huntington Bancshares, Wealth management, DeVita, Face, API, Citigroup, Insurance, Organizational founder, Bertolotti, Andreessen Horowitz, Behavior, MIT, First Horizon Bank, Doctor of Philosophy, Columbia University, General partnership, Friction, Transformation

Faced with higher interest rates and stress in the sector, banks have been seeking new, innovative options that can drive deposits.

Key Points: 
  • Faced with higher interest rates and stress in the sector, banks have been seeking new, innovative options that can drive deposits.
  • Faced with a rapidly evolving deposit landscape, banks across the country have turned to ModernFi to help manage their funding.
  • "In the face of unprecedented deposit outflows and extraordinary banking events, ModernFi's deposit network delivers critical stability and control over deposit management.
  • With their strategic position and track record, we're confident ModernFi will further catalyze growth and provide crucial support to American banks."

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting

Retrieved on: 
Monday, October 3, 2022
Manuscript, GLOBE, Hospital, Trial of the century, Mortality, Adult, Time, SEC, DeVita, Nasdaq, WR, ALD, Randomized controlled trial, Private Securities Litigation Reform Act, CEO, COVID-19, Lenox Hill Hospital, Ultrafiltration, Growth, Weight loss, Heart failure, Particle-size distribution, Overload, Safety, Quality of life, Science, HF, Diuretic, Patient, CV, Nephrology, Forward-looking statement, Division, Win, AUF, Company, Hypervolemia, Quality-adjusted life year, Pharmaceutical industry, Medicine, DRS

The results of the analysis performed using the Finkelstein-Schoenfeld method of Win-Ratios (WR) demonstrated a statistically superior benefit when using ultrafiltration over diuretics for fluid-overloaded heart failure patients.

Key Points: 
  • The results of the analysis performed using the Finkelstein-Schoenfeld method of Win-Ratios (WR) demonstrated a statistically superior benefit when using ultrafiltration over diuretics for fluid-overloaded heart failure patients.
  • The results favored ultrafiltration over diuretics in reducing heart failure events within 30 days and cardiovascular mortality within 90 days.
  • Adjustable Ultrafiltration (AUF) was statistically superior compared to Adjustable IV Loop Diuretics (ALD) with 81% more wins (Win Ratio=1.81, p=0.0429).
  • Nuwellis is committed to making Aquadex therapy the standard of care for fluid management in heart failure patients that are unresponsive to diuretics.

Nuwellis Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

Retrieved on: 
Tuesday, July 26, 2022
Time, Heart failure, GLOBE, Mortality, Hospital, Ultrafiltration, Trial of the century, CEO, Forward-looking statement, SEC, Hypervolemia, Overload, Private Securities Litigation Reform Act, University, Randomized controlled trial, Applied science, HF, COVID-19, Safety, Adult, Quality of life, Company, Heart, Science, Patient, Particle-size distribution, Nasdaq, Sodium, DeVita, Manuscript, Diuretic, Growth, HF2, WR, Pharmaceutical industry, Medicine, DRS

The study was trending favorably when the study sponsor terminated it before reaching full enrollment for reasons unrelated to patient safety or clinical futility.

Key Points: 
  • The study was trending favorably when the study sponsor terminated it before reaching full enrollment for reasons unrelated to patient safety or clinical futility.
  • At the time, analysis of the AVOID-HF trial data was inconclusive due to the lower-than-planned sample size.
  • We hope the AVOID-HF Win-Ratios analysis is accepted as a Late Breaking Clinical Trial at HFSA, and we are excited to share these results with the broader heart failure community.
  • Nuwellis also submitted information on REVERSE-HF to HFSAs Clinical Trials Central, as a currently enrolling heart failure randomized controlled trial.

Nuwellis Announces First Patient Enrolled in its Pivotal Trial REVERSE-HF

Retrieved on: 
Wednesday, June 29, 2022
Ultrafiltration, Science, Patient, Northwell Health, CEO, Adult, Trial of the century, Hospital, GLOBE, Lenox Hill Hospital, COVID-19, Growth, Heart failure, Division, Company, Mortality, DeVita, Overload, Heart, Hypervolemia, Society, Private Securities Litigation Reform Act, University, Nasdaq, Quality of life, SEC, Sodium, Nephrology, Diuretic, Safety, IV, HF, Forward-looking statement, Randomized controlled trial, Pharmaceutical industry, Medicine, Medicine, DRS

MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the companys pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study.

Key Points: 
  • MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the companys pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study.
  • The first patient was enrolled by Dr. Sirish Vullaganti, M.D.
  • "Heart failure is among the leading causes of hospitalizations due to the accumulation of fluid requiring decongestion in the hospital setting.
  • The first patient enrolled in REVERSE-HF marks an exciting milestone in this study, said Nestor Jaramillo, Jr., President and CEO of Nuwellis.

LIVEONE AND 131 LIVE ANNOUNCE GLOBAL PAY-PER-VIEW PERFORMANCE BTBT: PERFORMANCE FANCON FOR K-POP RAPPER B.I

Retrieved on: 
Monday, June 13, 2022
Destiny, Company, Greeting, Grammy Awards, Spotify, R&B, VIP, Sale, IOS, Android, Technology, STIRR, Music, Destiny Rogers, DJ Khaled, U.S. Securities and Exchange Commission, Roku, Radio, CEO, Partnership, Male, PPV, AOMG, LOS, Merchandising, LiveXLive, Apple TV, Greetings from Out Here, Time, Non-fungible token, ITunes, COVID-19, Annual report, Amazon Fire tablet, OTT, IKon, Acquisition, Du (company), Compliance, LOVE, Lost at Sea, SEC, LVO, COSMOS, Private Securities Litigation Reform Act, Bipolar Sunshine, Sensation, Program, DeVita, Sea, Slacker, NASDAQ, Time (magazine), Twitter, Long Time Gone, Stereotype, B.I, TikTok, TIME, Latto, PodcastOne, Facebook, Devita, Instagram

The live PPV event is scheduled for June 25th 11 PM EDT / June 26th at 12 PM KST, with rewatch tickets also available.

Key Points: 
  • The live PPV event is scheduled for June 25th 11 PM EDT / June 26th at 12 PM KST, with rewatch tickets also available.
  • The full fan con PPV performance on LiveOne will offer fans a deeper experience with exclusive behind-the-scenes footage.
  • "LiveOne is thrilled to continue its partnership with B.I and his team," said Robert Ellin, CEO and Chairman of LiveOne.
  • "B.I's previous PPV performance for his album Waterfall was a global success and his music continues to top LiveOne's charts.

Nuwellis Announces IRB Approval to Begin Its REVERSE-HF Clinical Study

Retrieved on: 
Tuesday, March 15, 2022
SEC, Trial of the century, University, Human, GLOBE, Â, Overload, Patient, Review, Heart failure, Lenox Hill Hospital, Private Securities Litigation Reform Act, FDA, Nasdaq, Grey Literature International Steering Committee, Heart, COVID-19, Hypervolemia, Science, Forward-looking statement, Hospital, Certified IRB Professional, Diuretic, Adult, Company, Research, Ultrafiltration, CEO, DeVita, Growth, Clinical research, Randomized controlled trial, Division, Committee, IRB, Nephrology, Biomedical Research, Institutional review board, Pharmaceutical industry, DRS, Medicine

REVERSE-HF is a multicenter, open-label, randomized controlled trial that will be conducted across the United States.

Key Points: 
  • REVERSE-HF is a multicenter, open-label, randomized controlled trial that will be conducted across the United States.
  • IRB approval of the study protocol marks a key step forward in beginning the REVERSE-HF study, said Megan Cease, Director of Clinical Research and Reimbursement of Nuwellis.
  • An IRB is a group that operates under FDA regulations and has been formally designated to review and monitor biomedical research involving human subjects.
  • Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Recovery Unplugged Welcomes New Chief Growth Officer Angelo Devita

Retrieved on: 
Monday, May 13, 2019
Unplugged, DeVita, Recovery

FORT LAUDERDALE, Fla., May 13, 2019 /PRNewswire/ -- Recovery Unplugged Treatment Centers is pleased to announce the arrival of veteran healthcare thought leader and sales executive Angelo Devita, MPH as its new Chief Growth Officer.

Key Points: 
  • FORT LAUDERDALE, Fla., May 13, 2019 /PRNewswire/ -- Recovery Unplugged Treatment Centers is pleased to announce the arrival of veteran healthcare thought leader and sales executive Angelo Devita, MPH as its new Chief Growth Officer.
  • Angelo Devita brings a singular combination of sales knowledge, healthcare industry experience and insight into music-based medicine to his new role at Recovery Unplugged.
  • Recovery Unplugged welcomes Mr. Devita at a time when the organization is poised to open more treatment centers across the United States.
  • "Angelo's background, skills and insights make him the ideal candidate to help Recovery Unplugged grow on all fronts and offer music-based addiction care to more Americans in need," says Recovery Unplugged Co-Founder and Chief Strategy Officer Paul Pellinger.